Skip to main content
main-content

Medication

Anti-obesity medications

07-18-2019 | Liraglutide (obesity) | News

Brain may put brakes on liraglutide weight loss effect

A small neuroimaging study suggests that taking liraglutide over the medium to long term may provoke a counter-regulatory response in the brain, diminishing the medication’s weight loss effect.

06-06-2019 | Liraglutide (T2DM) | News

Liraglutide may be an option for people with unresolved type 2 diabetes after metabolic surgery

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

12-14-2018 | Sleep apnea | Editorial | Article

Diabetes and obstructive sleep apnea syndrome: Double trouble

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

10-05-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

08-17-2018 | Semaglutide | Highlight | News

Semaglutide shows promise for weight management

Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.

04-13-2018 | Obesity | Review | Article

Treatment of adolescent obesity

Steinbeck KS et al. Nature Reviews Endocrinology 2018. doi: 10.1038/s41574-018-0002-8

04-03-2018 | Obesity | Review | Article

Racial disparities in obesity treatment

Byrd AS, Toth AT, Stanford FC. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0301-3

03-05-2018 | Obesity | Review | Article

Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon

Srivastava G, Apovian C. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0300-4

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

10-13-2017 | Obesity | Review | Article

Current pharmacotherapy for obesity

​​​​​​​Nat Rev Endocrinol 2017; 14: 12–24. doi: 10.1038/nrendo.2017.122

11-06-2017 | Prediabetes | News

Lifestyle interventions have most staying power for diabetes prevention

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.

08-23-2017 | Obesity | Review | Article

Weight management in patients with type 1 diabetes and obesity

Mottalib A et al. Curr Diab Rep 2017; 17: 92. doi: 10.1007/s11892-017-0918-8

07-31-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

06-23-2017 | Obesity | Review | Article

Pharmacotherapy in the management of pediatric obesity

Kelly AS, Fox CK. Curr Diab Rep 2017; 17: 55. doi: 10.1007/s11892-017-0886-z

01-18-2017 | Obesity | Review | Article

Medical management of diabesity: Do we have realistic targets?

Pappachan JM, Viswanath AK. Curr Diab Rep 2017; 17: 4. doi: 10.1007/s11892-017-0828-9

07-07-2017 | Liraglutide (obesity) | Updates | News

NICE evidence summary for liraglutide use in obese and overweight adults

The National Institute For Health and Care Excellence has issued an evidence summary to support use of the glucagon-like peptide-1 receptor agonist liraglutide in obese and overweight individuals with risk factors, such as dysglycemia.

05-14-2017 | Obesity | Review | Article

Medication use for the treatment of diabetes in obese individuals

Wilding JPH. Diabetologia 2017; 61: 265–272. doi: 10.1007/s00125-017-4288-1

04-19-2017 | Obesity | Review | Article

Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?

Roberts CA et al. Acta Diabetol 2017; 54: 715–725. doi: 10.1007/s00592-017-0994-x

01-20-2017 | Obesity | Patient and physician’s perspective | Article

Behavior modification: A patient and physician’s perspective

A patient affected by obesity discusses her experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism.

Image Credits